🇺🇸 FDA
Pipeline program

CAR-T Re-treatment

CAR-T re-treatment-MM

Phase 1 small_molecule active

Quick answer

CAR-T Re-treatment for Multiple Myeloma is a Phase 1 program (small_molecule) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Legend Biotech Corp
Indication
Multiple Myeloma
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials